Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Basni, Jodhpur, India.
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Basni, Jodhpur, India.
Am J Obstet Gynecol MFM. 2024 Sep;6(9):101450. doi: 10.1016/j.ajogmf.2024.101450. Epub 2024 Aug 7.
Postpartum hemorrhage (PPH) is an obstetrical emergency that occurs in 1% to 10% of all deliveries and contributes to nearly one-quarter of all maternal deaths worldwide. Tranexamic acid has been established as an adjunct in the treatment of PPH but its role in its prevention of PPH following vaginal delivery has not been widely studied.
This study aimed to assess the effect of prophylactic tranexamic acid (1 g) along with active management of the third stage of labor in reducing postpartum blood loss and the incidence of postpartum hemorrhage after vaginal delivery.
In this randomized controlled trial, 650 women with singleton pregnancies at ≥34 weeks of gestation who were undergoing vaginal delivery were included. Eligible women were randomly assigned to receive either 1 g of tranexamic acid or placebo intravenously along with active management of the third stage of labor. Calibrated blood collection bags were used to measure postpartum blood loss during the third and fourth stages of labor.
Of 886 women approached for the study, 650 who met the inclusion criteria were enrolled, and 320 in group A and 321 in group B were analyzed. The maternal characteristics were similar between the groups. The mean blood loss did not differ significantly between the intervention and placebo groups (378.5±261.2 mL vs 383.0±258.9 mL; P=.93). The incidence of primary postpartum hemorrhage was comparable in both groups (15.9% in group A and 15.3% in group B; P=.814). The median quantitative decreases in hemoglobin levels within 12 to 24 hours after delivery were 0.60 g% (interquartile range, 0.40-0.90) in group A and 0.60 g% (interquartile range, 0.40-0.80) in group B, which were comparable in both groups (P=.95). The most common adverse effect reported was dizziness, and there was no thromboembolic event at 3 months follow-up in either group.
The use of tranexamic acid as a prophylactic measure along with active management of the third stage of labor does not provide additional benefit in reducing the postpartum blood loss and incidence of postpartum hemorrhage after vaginal delivery. El resumen está disponible en Español al final del artículo.
产后出血(PPH)是一种在 1%至 10%的分娩中发生的产科急症,导致全球近四分之一的产妇死亡。氨甲环酸已被确立为治疗 PPH 的辅助药物,但它在预防阴道分娩后 PPH 中的作用尚未得到广泛研究。
本研究旨在评估预防性使用氨甲环酸(1 克)联合第三产程积极管理,以减少阴道分娩后产后出血量和产后出血的发生率。
在这项随机对照试验中,纳入了 650 名孕周≥34 周、单胎妊娠、行阴道分娩的孕妇。符合条件的孕妇被随机分配接受静脉注射 1 克氨甲环酸或安慰剂,并联合第三产程积极管理。使用校准的集血袋测量第三和第四产程的产后出血量。
在纳入研究的 886 名女性中,有 650 名符合纳入标准的女性入组,其中 A 组 320 名,B 组 321 名。两组的产妇特征相似。干预组和安慰剂组的平均出血量无显著差异(378.5±261.2 毫升 vs 383.0±258.9 毫升;P=.93)。两组原发性产后出血的发生率相似(A 组 15.9%,B 组 15.3%;P=.814)。产后 12 至 24 小时内血红蛋白水平的中位数定量下降分别为 A 组 0.60 克%(四分位距,0.40-0.90)和 B 组 0.60 克%(四分位距,0.40-0.80),两组间无显著差异(P=.95)。报告的最常见不良反应是头晕,两组在 3 个月随访时均无血栓栓塞事件。
在第三产程积极管理的基础上预防性使用氨甲环酸并不能提供额外的益处,不能减少阴道分娩后产后出血量和产后出血的发生率。